Patents by Inventor Jae Ha Ryu

Jae Ha Ryu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250340591
    Abstract: A compound according to the present invention or a pharmaceutically acceptable salt thereof selectively and specifically acts as an agonist for GPR39, promotes the proliferation of intestinal tissue cells and enterohepatic association, promotes cell differentiation, and alleviates inflammation in inflamed intestinal tissue. Thus, the compound can be utilized in a composition for alleviating and mitigating, preventing, or treating inflammatory bowel disease.
    Type: Application
    Filed: September 8, 2022
    Publication date: November 6, 2025
    Inventors: Jae-Il KIM, Gyeong Min KIM, Jae Ha RYU, Sang Hyun JOO, Ye Ga PARK
  • Patent number: 12383605
    Abstract: The present invention pertains to an exenatide analogue glycosylated to a specific residue, and a use thereof. The present invention provides a novel substance for treating diabetes, the novel substance exhibiting improved in vivo stability compared to conventional exenatides and analogues thereof. The present invention pertains to an exenatide dimer analogue and a use thereof. The present invention provides a novel substance for treating diabetes and obesity, the novel substance exhibiting significantly improved in vivo stability compared to conventional exenatides and analogues thereof.
    Type: Grant
    Filed: August 13, 2020
    Date of Patent: August 12, 2025
    Assignee: ANYGEN CO., LTD.
    Inventors: Jae Ha Ryu, Sang Hyun Joo, Ye Ga Park
  • Publication number: 20230287044
    Abstract: The present invention relates to a novel antibacterial peptide and a composition comprising the same as an active ingredient. The novel antibacterial peptide of the present invention exhibits excellent antibacterial activity against antibiotic-resistant bacteria as well as Gram-positive bacteria and Gram-negative bacteria and is low in cytotoxicity and, as such, can be advantageously utilized as an active ingredient in an antibiotic, a cosmetic composition, a food additive, a feed additive, a biotic pesticide, a quasi-drug product, and the like.
    Type: Application
    Filed: March 30, 2021
    Publication date: September 14, 2023
    Inventors: Jae Il KIM, Jae Ha RYU, Shang Hyeon KIM, Sol LEE
  • Publication number: 20230212222
    Abstract: The present invention relates to a novel compound and a composition for an anti-diabetes and anti-obesity comprising the same as an active ingredient. The compound or pharmaceutically acceptable salt thereof according to the present invention selectively and specifically acts as an agonist of GPR39, activates the mechanism of glucose-dependent insulin secretion in pancreatic beta cells, and significantly increases glucose tolerance and an anti-diabetic effect, and therefore can be utilized as a composition for improving, preventing, or treating diabetes mellitus. In addition, the compound or pharmaceutically acceptable salt thereof according to the present invention acts on GPR39 so as to have lipolytic ability in adipocytes and adipose tissue, and therefore can be utilized as a composition for improving, preventing, or treating obesity.
    Type: Application
    Filed: March 11, 2021
    Publication date: July 6, 2023
    Inventors: Jae Il KIM, Jae Ha RYU, Bong Gyu PARK
  • Publication number: 20220323548
    Abstract: The present invention pertains to an exenatide analogue glycosylated to a specific residue, and a use thereof. The present invention provides a novel substance for treating diabetes, the novel substance exhibiting improved in vivo stability compared to conventional exenatides and analogues thereof. The present invention pertains to an exenatide dimer analogue and a use thereof. The present invention provides a novel substance for treating diabetes and obesity, the novel substance exhibiting significantly improved in vivo stability compared to conventional exenatides and analogues thereof.
    Type: Application
    Filed: August 13, 2020
    Publication date: October 13, 2022
    Inventors: Jae Ha RYU, Sang Hyun JOO, Ye Ga PARK
  • Patent number: 7884129
    Abstract: The present invention is related to an alcohol compound isolated from the extract of Cucurbitaceae family plant having anti-adipogenic and anti-obesity activity, and a composition comprising the same. The compound showed potent reducing activity of body weight, decreasing effect on the blood triglyceride and cholesterol level, activating activity of PPAR ? and preventing activity from the adipogenesis of precursor fat cells with no toxicity, therefore, those extract can be useful in treating or preventing obesity and adipogenesis-involved diseases as a medicine or health care food.
    Type: Grant
    Filed: May 20, 2008
    Date of Patent: February 8, 2011
    Assignee: Helixir Co., Ltd.
    Inventors: Mi Rim Jin, Jae Ha Ryu, Hyoun Jeong Choi, Hyun Jin Jung, Kyoung Chul Park, Sun Young Kim
  • Publication number: 20080280976
    Abstract: The present invention is related to an alcohol compound isolated from the extract of Cucurbitaceae family plant having anti-adipogenic and anti-obesity activity, and a composition comprising the same. The compound showed potent reducing activity of body weight, decreasing effect on the blood triglyceride and cholesterol level, activating activity of PPAR ? and preventing activity from the adipogenesis of precursor fat cells with no toxicity, therefore, those extract can be useful in treating or preventing obesity and adipogenesis-involved diseases as a medicine or health care food.
    Type: Application
    Filed: May 20, 2008
    Publication date: November 13, 2008
    Applicant: HELIXIR CO., LTD
    Inventors: Mi Rim JIN, Jae Ha RYU, Hyoun Jeong CHOI, Hyun Jin JUNG, Kyoung Chul PARK, Sun Young KIM